Premium Article - Tuesday, 29 September 2009
Europe’s competition commissioner, Neelie Kroes, today told drugmakers to expect new investigations into the pharmaceutical industry in a speech to the Committee on Economic and Monetary Affairs.
Premium Article - Tuesday, 18 August 2009
Pharmaceutical companies Bayer and Barr have challenged a US Department of Justice antitrust division brief in a US appellate court, which said reverse payment settlements between brand and generic drugs companies are “presumptively unlawful”.
Premium Article - Wednesday, 15 July 2009
The US Senate Health, Education, Labor and Pensions (HELP) Committee has approved an amendment to a health bill that would grant brand-name biologic drugmakers 12 years' immunity from generic competition to a new product.
Premium Article - Wednesday, 15 July 2009
Featured In: July 2009 (Vol. 12 Iss. 6)
Independent practitioner Richard Wolfram, co-author of an amicus brief supporting the US Federal Trade Commission's unsuccessful petition for review by the Supreme Court in FTC v Rambus, revisits the upside-down "but for" world of the Court of Appeals' decision, which reversed the FTC decision
Premium Article - Wednesday, 15 July 2009
Featured In: July 2009 (Vol. 12 Iss. 6)
How should antitrust agencies enforce laws on monopolies and unilateral conduct without stifling the competition and innovation they are supposed to foster? GCR invited six leading specialists to Washington, DC to discuss the future of Section 2 enforcement in the US, and how agencies across the world should approach some of the thorniest issues in competition enforcement today
Premium Article - Monday, 08 June 2009
Three private damages actions against pharmaceutical companies that reached ‘reverse payment' settlements relating to a testosterone replacement drug have been transferred to an Atlanta court.
Premium Article - Friday, 05 June 2009
A US House of Representatives competition subcommittee met this week to discuss legislation that would prohibit pharmaceutical patent settlements that delay the introduction of generic drugs.
Premium Article - Wednesday, 06 May 2009
Germany's Federal Court of Justice has ruled that a company holding essential patents for a technology standard can be considered dominant, but that refusing to license its patents does not of itself constitute an abuse.
Premium Article - Friday, 24 April 2009
The US court for the Federal Circuit has remanded part of an appeal against a patent infringement decision. The appeal alleges that Philips misused its patents by agreeing with a competitor not to license patents to competing technologies outside of a patent pool.
Premium Article - Wednesday, 15 April 2009
Featured In: April 2009 (Vol. 12 Iss. 4)
Despite US court decisions, competition agencies are determined to make their presence felt in the realm of IP. Peter Scott explains
Premium Article - Tuesday, 14 April 2009
A California district court has transferred to Georgia a suit filed by the US Federal Trade Commission against pharmaceutical companies who entered into a ‘reverse payment settlement'.
Premium Article - Tuesday, 07 April 2009
Andrew Bodnar, a former senior executive at pharmaceutical company Bristol-Myers Squibb, has pleaded guilty to his role in the company misleading the US Federal Trade Commission over a patent litigation settlement.
Premium Article - Thursday, 02 April 2009
The US Federal Trade Commission has fined drug maker Bristol-Myers Squibb more than US$2 million for making a false oath to the authority about parts of a settlement agreement with a generic drug manufacturer.
Premium Article - Tuesday, 24 March 2009
The US Supreme Court may have the final say on whether pharmaceutical companies that own patents for name-brand drugs have the right to pay their rivals to slow or prevent the introduction of generic substitutes.
Premium Article - Thursday, 12 March 2009
An associate general counsel of Microsoft has called for the treatment of IP rights within antitrust policy to be equated with that of contractual rights, at a conference in Miami.
Back to top
